Replies to post #109968 on Biotech Values

[jq1234]

EXEL is conducting 150-patient trial in CRPC to see if they can develop composite endpoint. In my opinion, EXEL should also go for simple OS endpoint concurrently. All they need is more data to decide the size of trial.